Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

71.4%

5 terminated/withdrawn out of 7 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05215119Completed

Immediate Versus Delayed Natural Cycle Frozen Embryo Transfers

Role: lead

NCT04744844Not ApplicableTerminated

DNA Amplification in Blastocoel Fluid

Role: lead

NCT03095053Not ApplicableCompleted

PGT-A Versus Blastocyst Morphology Selection

Role: lead

NCT02788097Not ApplicableTerminated

Comparison of Day 19 and Day 20 Artificial FET

Role: lead

NCT01987856Not ApplicableWithdrawn

Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle

Role: lead

NCT01979341Not ApplicableWithdrawn

The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes

Role: lead

NCT02238431Not ApplicableWithdrawn

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

Role: lead

All 7 trials loaded